Published in Gynecol Oncol on December 22, 2011
Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol (2015) 5.37
Ovarian cancer screening--current status, future directions. Gynecol Oncol (2013) 1.06
Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med (1996) 46.18
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials (2000) 10.99
Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol (2001) 10.16
What do we mean by validating a prognostic model? Stat Med (2000) 9.18
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med (2000) 3.25
Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer (1995) 2.64
Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med (2009) 1.94
A multivariate logistic regression equation to screen for diabetes: development and validation. Diabetes Care (2002) 1.83
Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol (2003) 1.75
The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecol Oncol (2008) 1.14
Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol (1995) 1.12
Prostate-specific antigen velocity and prostate cancer gleason grade and stage. Cancer (2007) 1.09
Prognostic models based on literature and individual patient data in logistic regression analysis. Stat Med (2000) 1.08
Early serum CA125 response and outcome in epithelial ovarian cancer. Eur J Cancer (1990) 1.01
CA125 based diagnosis and therapy in recurrent ovarian cancer. Anticancer Res (1997) 0.81
The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer. Gynecol Oncol (1992) 0.80
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
Breast-cancer risk in families with mutations in PALB2. N Engl J Med (2014) 4.97
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Building a research consortium of large health systems: the Cancer Research Network. J Natl Cancer Inst Monogr (2005) 4.92
The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res (2004) 4.54
Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med (2011) 4.47
Selection criteria for lung-cancer screening. N Engl J Med (2013) 3.69
Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol (2009) 3.59
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int (2008) 3.51
Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol (2005) 3.25
Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. J Natl Cancer Inst (2010) 3.16
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2005) 3.01
Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res (2006) 2.95
Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst (2005) 2.82
Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer (2005) 2.79
Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol (2012) 2.62
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol (2004) 2.44
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials (2010) 2.38
Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. J Natl Cancer Inst (2011) 2.31
Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst (2005) 2.27
Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Natl Cancer Inst (2005) 2.24
Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev (2009) 2.20
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Folate intake, alcohol use, and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Am J Clin Nutr (2006) 2.08
Man's best friend? The effect of pet ownership on house dust microbial communities. J Allergy Clin Immunol (2010) 2.06
A web-based, tailored asthma management program for urban African-American high school students. Am J Respir Crit Care Med (2007) 1.96
Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med (2009) 1.94
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer (2002) 1.89
House dust exposure mediates gut microbiome Lactobacillus enrichment and airway immune defense against allergens and virus infection. Proc Natl Acad Sci U S A (2013) 1.88
Incidence of nonmelanoma skin cancer in a cohort of patients with vitiligo. J Am Acad Dermatol (2009) 1.71
Reduction in antibiotic use among US children, 1996-2000. Pediatrics (2003) 1.71
Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet (2010) 1.56
Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst (2012) 1.53
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) 1.51
Identification of patients with nonmelanoma skin cancer using health maintenance organization claims data. Am J Epidemiol (2009) 1.51
Relationship of house-dust mite allergen exposure in children's bedrooms in infancy to bronchial hyperresponsiveness and asthma diagnosis by age 6 to 7. Ann Allergy Asthma Immunol (2003) 1.51
Prospective study of fruit and vegetable intake and risk of prostate cancer. J Natl Cancer Inst (2007) 1.49
Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Canc Netw (2014) 1.48
Differences in allergic sensitization by self-reported race and genetic ancestry. J Allergy Clin Immunol (2008) 1.47
BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol (2007) 1.43
Gene-environment interactions with CD14 C-260T and their relationship to total serum IgE levels in adults. J Allergy Clin Immunol (2006) 1.42
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research. Breast Cancer Res Treat (2008) 1.40
Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf (2007) 1.39
Race-ethnicity, crime, and other factors associated with adherence to inhaled corticosteroids. J Allergy Clin Immunol (2006) 1.36
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2013) 1.29
Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. J Natl Cancer Inst (2010) 1.29
Estimating the cumulative risk of a false-positive test in a repeated screening program. Biometrics (2004) 1.27
Statistical issues in randomized trials of cancer screening. BMC Med Res Methodol (2002) 1.27
Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination. J Natl Cancer Inst (2012) 1.27
Effects of BRCA1 and BRCA2 mutations on female fertility. Proc Biol Sci (2011) 1.24
Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci U S A (2002) 1.23
Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort. BMC Cancer (2009) 1.22
Colorectal cancers not detected by screening flexible sigmoidoscopy in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Gastrointest Endosc (2012) 1.18
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 1.17
Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. Hum Mol Genet (2010) 1.16
Racial and age differences in colon examination surveillance following a diagnosis of colorectal cancer. J Natl Cancer Inst Monogr (2005) 1.16
The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecol Oncol (2008) 1.14
Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial. Int J Cancer (2012) 1.11
Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies. PLoS Med (2013) 1.11
Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res (Phila) (2011) 1.10